生物技术公司CytomX（CTMX）在周四盘后交易中股价大跌5.49%，引起投资者关注。这一显著下跌紧随公司发布的令人失望的第三季度财报。
根据最新财报显示，CytomX第三季度营收仅为596.3万美元，远低于分析师预期的1160万美元。这一巨大差距凸显了公司在收入增长方面面临的严峻挑战。同时，公司第三季度运营支出达到2173.1万美元，进一步加剧了投资者对公司财务状况的担忧。
CytomX作为一家专注于开发新型抗体疗法的生物技术公司，其收入主要来源于研发合作和里程碑付款。这次营收大幅低于预期可能表明公司在推进其管线项目或达成新的合作协议方面遇到了困难。投资者对公司未来盈利能力的担忧似乎是导致股价在盘后交易中大幅下跌的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.